eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2018
vol. 14
 
Share:
Share:
more
 
 
abstract:
Clinical research

CXCL9 concentrations in cerebrospinal fluid and serum of patients with tick-borne encephalitis

Olga M. Koper, Joanna Kamińska, Sambor Grygorczuk, Joanna Zajkowska, Halina Kemona

Arch Med Sci 2018; 14, 2: 313–320
Online publish date: 2016/03/22
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction: The aim of our current study was to evaluate cerebrospinal fluid (CSF) and serum CXCL9 concentrations and diagnostic usefulness of this molecule in tick-borne encephalitis (TBE). The study included TBE patients in the acute phase (TBE I) and after 2 weeks of follow-up (TBE II). The control group consisted of patients investigated for suspected central nervous system (CNS) infection, but with normal CSF findings.

Material and methods: Concentrations of CXCL9 were measured using enzyme-linked immunosorbent assay (ELISA).

Results: Cerebrospinal fluid and serum concentrations of CXCL9 in patients with TBE were significantly higher than in controls (p < 0.001). This alteration was also observed in the case of the CXCL9 index (ICXCL9; CSF CXCL9 concentration divided by serum CXCL9 concentration) (p < 0.001); moreover, ICXCL9 significantly decreased after 2 weeks (p < 0.001). This is the first study to evaluate the CSF and serum levels of CXCL9 in subjects with TBE.

Conclusions: CXCL9 is a ligand for CXCR3, which was found on all Th1 memory lymphocytes present in the peripheral blood; therefore the elevated concentrations of CXCL9 in TBE patients as compared to the controls might indicate that this chemokine perhaps takes part in the trafficking of Th1 cells into the CNS. The results presented here support the hypothesis that CXCL9 may play a role in TBE. However, further studies are required to determine whether this protein might be used as a potential tool for the diagnosis and monitoring of inflammation in TBE.
keywords:

chemokines, cerebrospinal fluid, tick-borne encephalitis

references:
Süss J. Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia – an overview. Ticks Tick Borne Dis 2011; 2: 2-15.
Gritsun TS, Lashkevich VA, Gould EA. Tick-borne encephalitis. Antivir Res 2003; 57: 129-46.
Bogovic P, Lotric-Furlan S, Strle F. What tick-borne encephalitis may look like: clinical signs and symptoms. Travel Med Infect Dis 2010; 8: 246-50.
Lindquist L, Vapalahti O. Tick-borne encephalitis. Handb Clin Neurol 2008;371: 1861-71.
Puchhammer-Stöckl E, Kunz C, Mandl CW, Heinz FX. Identification of tick-borne encephalitis virus ribonucleic acid in tick suspensions and in clinical specimens by a reverse transcription-nested polymerase chain reaction assay. Clin Diagn Virol 1995; 4: 321-6.
Mazur G, Jaskuła E, Kryczek I, et al. Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin’s lymphoma. Folia Histochem Cytobiol 2011; 49: 240-7.
Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 2001; 22: 147-84.
Banisadr G, Rostène W, Kitabgi P, Parsadaniantz SM. Chemokines and brain functions. Curr Drug Targets
Inflamm Allergy 2005; 4: 387-99.
Guerreiro R, Santos-Costa Q, Azevedo-Pereira JM. The chemokines and their receptors: characteristics and physiological functions. Acta Med Port 2011; 24: 967-76.
Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 2002; 42: 469-99.
Müller M, Carter S, Hofer MJ, Campbell IL. Review: the chemokine receptor CXCR3 and its ligands CXCL9, CXCL10, and CXCL11 in neuroimmunity – a tale of conflict and conundrum. Neuropathol Appl Neurobiol 2010; 36: 368-87.
Ramesh G, MacLean AG, Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm 2013; 2013: 480739.
Rostène W, Kitabgi P, Parsadaniantz SM. Chemokines: a new class of neuromodulator? Nat Rev Neurosci 2007; 8: 895-903.
Sorce S, Myburgh R, Krause KH. The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol 2011; 93: 297-311.
Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42.
Bendall L. Chemokines and their receptors in disease. Histol Histopathol 2005; 20: 907-26.
Rupprecht TA, Koedel U, Muhlberger B, Wilske B, Fontana A, Pfister HW. CXCL11 is involved in leucocyte recruitment to the central nervous system in neuroborreliosis. J Neurol 2005; 252: 820-3.
Clark-Lewis I, Mattioli I, Gong JH, Loetscher P. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 2003; 278: 289-95.
Park MK, Amichay D, Love P, et al. The CXC chemokine murine monokine induced by IFN-gamma (CXC chemokine ligand 9) is made by APCs, targets lymphocytes including activated B cells, and supports antibody responses to a bacterial pathogen in vivo. Immunol 2002; 169: 1433-43.
Lian JQ, Yang XF, Zhao RR, et al. Expression profiles of circulating cytokines, chemokines and immune cells in patients with hepatitis B virus infection. Hepat Mon 2014; 14: e18892.
Yoon KC, Park CS, You IC, et al. Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci 2010; 51: 643-50.
Flier J1, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001; 194: 398-405.
Lepej SZ, Rode OD, Jeren T, Vince A, Remenar A, Barsić B. Increased expression of CXCR3 and CCR5 on memory CD4+ T-cells migrating into the cerebrospinal fluid of patients with neuroborreliosis: the role of CXCL10 and CXCL11. J Neuroimmunol 2005; 163: 128-34.
Zajkowska J, Moniuszko-Malinowska A, Pancewicz SA, et al. Evaluation of CXCL10, CXCL11, CXCL12 and CXCL13 chemokines in serum and cerebrospinal fluid in patients with tick borne encephalitis (TBE). Adv Med Sci 2011; 56: 311-7.
Lalkhen AG, McCluskey A. Clinical tests: sensitivity and specificity. Downloaded from http://ceaccp.oxfordjournals.org/ at Uniwersytet Medyczny w Bialymstoku on April 16, 2014.
Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: a prospective study of 656 patients. Brain 1999; 122: 2067-78.
Mickiene A, Laiskonis A, Günther G, Vene S, Lundkvist A, Lindquist L. Tick-borne encephalitis in an area of high endemicity in Lithuania: disease severity and long-term prognosis. Clin Infect Dis 2002; 35: 650-8.
Günther G, Haglund M, Lindquist L, Forsgren M, Sköldenberg B. Tick-bone encephalitis in Sweden in relation to aseptic meningoencephalitis of other etiology: a prospective study of clinical course and outcome. J Neurol 1997; 244: 230-8.
TomaŽič J, Ihan A. Flow cytometric analysis of lymphocytes in cerebrospinal fluid in patients with tick-borne encephalitis. Acta Neurol Scand 1997; 95: 29-33.
Holub M, Klucková Z, Beran O, Aster V, Lobovská A. Lymphocyte subset numbers in cerebrospinal fluid: comparison of tick-borne encephalitis and neuroborreliosis. Acta Neurol Scand 2002; 106: 302-8.
Bardina SV, Lim JK. The role of chemokines in the pathogenesis of neurotropic flaviviruses. Immunol Res 2012; 54: 121-32.
Gelpi E, Preusser M, Garzuly F, Holzmann H, Heinz FX, Budka H. Visualization of Central European tick-borne encephalitis infection in fatal human cases. J Neuropathol Exp Neurol 2005; 64: 506-12.
Gelpi E, Preusser M, Laggner U, et al. Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue. J Neurovirol 2006; 12: 322-7.
Wen X, Kudo T, Payne L, Wang X, Rodgers L, Suzuki Y. Predominant interferon-gamma-mediated expression of CXCL9, CXCL10, and CCL5 proteins in the brain during chronic infection with Toxoplasma gondii in BALB/c mice resistant to development of toxoplasmic encephalitis. J Interferon Cytokine Res 2010; 30: 653-60.
Sato T, Coler-Reilly A, Utsunomiya A, et al. CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis. PLoS Negl Trop Dis 2013; 7: e2479.
Wang SM, Lei HY, Yu CK, Wang JR, Su IJ, Liu CC. Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. J Infect Dis 2008; 198: 1002-6.
Ochiai E, Sa Q, Brogli M, et al. CXCL9 is important for recruiting immune T cells into the brain and inducing an accumulation of the T cells to the areas of tachyzoite proliferation to prevent reactivation of chronic cerebral infection with Toxoplasma gondii. Am J Pathol 2015; 185: 314-24.
Grygorczuk S, Mierzynska D, Zdrodowska A, et al. Tick-borne encephalitis in north-eastern Poland in 1997-2001: a retrospective study. Scand J Infect Dis 2002; 34: 904-9.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe